225ac−j591
mAbexperimentalADC
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 10, 2017 (NCT03276572)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Glutamate carboxypeptidase IIINHIBITOR
FOLH1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 225-Actinium
Oral
No
Parenteral
No
Topical
No
Also known as
- 225ac−j591
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05567770 | Phase 1 | Dec 31, 2022 | Convergent Therapeutics, Inc., Cornell University |
| NCT04946370 | Phase 1/Phase 2 (Phase 2) | Aug 12, 2021 | Cornell University, Department of Defense, Merck |
| NCT04886986 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2021 | Cornell University, POINT Biopharma |
| NCT04576871 | Early Phase 1 (Phase 1) | Oct 29, 2020 | Cornell University |
| NCT04506567 | Phase 1/Phase 2 (Phase 2) | Aug 18, 2020 | Cornell University |
| NCT03276572 | Phase 1 | Oct 10, 2017 | Cornell University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cornell University | Academic/Hospital | 6 | 6 | 2 | 2017 |
| Convergent Therapeutics, Inc. | For profit | 1 | 0 | 1 | 2022 |
| Department of Defense | Government | 1 | 0 | 1 | 2021 |
| Merck | For profit | 1 | 0 | 1 | 2021 |
| POINT Biopharma | For profit | 1 | 0 | 1 | 2021 |
5 organizations
Page 1 / 1